Lee et al. ( 1 ) recently reported the results of a randomized, double-blind, placebocontrolled trial in small cell lung cancer combining the anti-angiogenic drug thalidomide with carboplatin and etoposide chemotherapy. The addition of thalidomide to the chemotherapy regimen was associated with decreased survival of patients with extensive disease and increased risk of thromboembolic events (TEE). The authors proposed that the reason for poorer survival may be because of accelerated lung cancer progression or higher than recorded thrombosis-related death secondary to thalidomide. We would herein like to further expand on the authors ' assumptions guided by the editorial of Rüegg and Peters ( 2 ) , who suggested that a better understanding of the vascular biology of small cell lung cancer and the anti-angiogenic properties of thalidomide should be entertained.
The incidence of TEE in multiple myeloma patients receiving thalidomide has been extensively studied ( 3 ) . There is a general consensus that the incidence of TEE (<5%) is not substantially increased with the use of thalidomide as a single agent when compared with the use of standard chemo-and radiotherapy ( ~ 10%). However, the combination of thalidomide and chemotherapy resulted in TEE incidence as high as 58% ( 3 ). Most events have been recorded in the fi rst 60 days of therapy ( 3 ). Thus, the high incidence of TEE in the study by Lee et al. ( 1 ) , especially at the fi rst phase of the study comes at no surprise. Most previous reports on multiple myeloma also confi rmed that the incidence is even underestimated because studies that actively searched for the development of TEE, by using Doppler ultrasonography of the lower extremity or spiral computed tomography of the chest, revealed higher incidence ( 3 ). In the study by Lee et al. ( 1 ) , there was no mention as to whether thrombotic phenomena were actively looked for or if autopsies were undertaken to determine the cause of death. Hence, many deaths may have actually been because of TEE rather than progression of small cell lung cancer. Moreover, experience with multiple myeloma recommends the use of prophylactic anticoagulant therapy once thalidomide is combined to chemotherapy (especially in the initial 60 days of treatment) ( 3 ), which the authors did not implement; thus, leaving the TEE risk unbalanced.
Thalidomide has a wide spectrum of biological effects, including some that have been hypothesized to promote this high incidence of TEE. Such effects include transient elevation of factor VIII and von Willebrand factor, reduction of soluble thrombomodulin levels during the first month of therapy, and restoration of endothelial cell protease-activate receptor-1 expression after damage from cytotoxic agents ( 3 -5 ) . In primary lung cancer, protease-activate receptor-1 has been shown to induce proliferation of alveolar capillary endothelial cells after activation by serum thrombin and neoplastic cell-released trypsin ( 6 ) . These results suggested a synergistic effect of protease-activate receptor-1 with vascular endothelial growth factor in alveolar angiogenesis ( 6 ) . Thus, thalidomide may actually have more of a stimulating rather than an inhibitory role on angiogenesis in lung cancer.
We echo the call by Rüegg and Peters ( 2 ) for a more vivid investigation of the biology of small cell lung cancer. This will help identify potential molecular targets and optimize the choice of appropriate drugs that merit clinical investigation.
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